Barreto Camila Marques de Alcântara, do Valle Eliane Almeida, Moreira Jessica Pronestino de Lima, E Silva Katia Farias, Rosas Siane Lopes Bittencourt, Santana Patrícia Teixeira, Pittella Ana Maria, Pereira Gustavo, Fernandes Flavia Ferreira, Perez Renata de Mello, de Souza Heitor Siffert Pereira
Department of Clinical Medicine, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, 21941-913, Brazil; Bonsucesso Federal Hospital, Rio de Janeiro, 20950-003, Brazil.
Department of Clinical Medicine, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, 21941-913, Brazil; Pedro Ernesto University Hospital, Rio de Janeiro, 20551-030, Brazil.
Ann Hepatol. 2025 Jan-Jun;30(1):101567. doi: 10.1016/j.aohep.2024.101567. Epub 2024 Sep 12.
Microbial translocation contributes to cirrhosis progression and complications. This study aims to investigate whether molecules related to intestinal permeability or microbial translocation can serve as prognostic biomarkers in patients with decompensated cirrhosis.
We prospectively evaluated hospitalized patients with decompensated cirrhosis for liver function, complications during hospitalization, in-hospital mortality, composite outcomes of in-hospital mortality and complications, 12-month mortality, and survival rates. Blood samples were collected upon admission, and 1,3 beta-d-glucan, zonulin, calprotectin, and lipopolysaccharide-binding protein were measured using commercial kits.
Ninety-one patients with decompensated cirrhosis were enrolled. The mean age was 58 ± 12 years; 57% were male. The three main cirrhosis etiologies were hepatitis C (35%), alcohol (25%), and non-alcoholic steatohepatitis (17%). In terms of liver function, 52% were Child C, and 68% had model for end-stage liver disease ≥15. The in-hospital and one-year mortality rates were 31% and 57%, respectively. Child-Pugh, 1,3 beta-glucan, and model for end-stage liver disease were positively correlated; zonulin was associated with complications during hospitalization (acute kidney injury) and composite outcomes, and calprotectin was associated with all outcomes except 12-month mortality.
Serum calprotectin and zonulin levels emerge as noninvasive prognostic biomarkers for potentially unfavorable outcomes in patients with decompensated cirrhosis.
微生物易位会促使肝硬化进展并引发并发症。本研究旨在探究与肠道通透性或微生物易位相关的分子是否可作为失代偿期肝硬化患者的预后生物标志物。
我们对住院的失代偿期肝硬化患者进行前瞻性评估,内容包括肝功能、住院期间并发症、院内死亡率、院内死亡率和并发症的综合结局、12个月死亡率以及生存率。入院时采集血样,使用商用试剂盒检测1,3-β-d-葡聚糖、闭合蛋白、钙卫蛋白和脂多糖结合蛋白。
共纳入91例失代偿期肝硬化患者。平均年龄为58±12岁;57%为男性。肝硬化的三大主要病因是丙型肝炎(35%)、酒精(25%)和非酒精性脂肪性肝炎(17%)。就肝功能而言,52%为Child C级,68%的终末期肝病模型评分≥15分。院内死亡率和1年死亡率分别为31%和57%。Child-Pugh评分、1,3-β-葡聚糖和终末期肝病模型呈正相关;闭合蛋白与住院期间并发症(急性肾损伤)和综合结局相关,钙卫蛋白与除12个月死亡率外的所有结局相关。
血清钙卫蛋白和闭合蛋白水平可作为失代偿期肝硬化患者潜在不良结局的非侵入性预后生物标志物。